Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Inflammation as triggering of metastasis
- Foreword
- Data presented in 1993
- Relapse for postmenopausal Milan patients (1)
- Relapse for postmenopausal Milan patients (2)
- Milan data presented in disease
- Probability diease free
- The continuous growth model
- Results of computer simulation (1)
- Results of computer simulation (2)
- Similar relapse patterns seen in other cancer sites
- Was this effect known 2,000 years ago?
- Can this explain important clinical observations?
- Adjuvant chemotherapy and relapse hazard
- Most important finding
- June 2010 – an unexpected and dramatic report
- Forget et al. data
- PUB-Med listings of “ketorolac” in title
- What mechanism could explain Forget et al. data?
- Wounding-immunology-inflammation-oncology (1)
- Wounding-immunology-inflammation-oncology (2)
- Wounding-immunology-inflammation-oncology (3)
- Wounding-immunology-inflammation-oncology (4)
- Animal model is similar to breast cancer data
- Surgery might promote growth of metastases
- A retrospective study of perioperative NSAID
- Three types of responses on the internet
- Perioperative ketorolac prevents early relapses
- Do we know all the possible mechanisms?
- Triple negative recurrence – Milan data
- Forget et al. retrospective data
- Randomized clinical trial of tranexamic
- Conclusions (1)
- Conclusions (2)
- Relevant publications
- Disclosure
- Collaborators
- Thanks
Topics Covered
- Primary cancer surgery
- Systemic inflammation
- Metastatic amplification
- Perioperative inflammation as triggering origin of metastasis development
- Hazards of relapse
- Computer simulations and clinical observations
- The linkage between wounding, immunology, inflammation and oncology
- Ketorolac and the uses of perioperative NSAIDs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Retsky, M. (2019, January 31). Solution proposed to a 2000 year old problem in oncology [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/TMUK2940.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Michael Retsky has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. This is Michael Retsky.
I am on staff at Harvard TH Chan School of Public Health.
And I have a small business,
Late Relapses, LLC. That's a startup.
0:13
What I'm going to describe to you is a research project in
cancer that is far different from the usual research.
Romano Demicheli and myself edited a book published by
Springer Nature: "Perioperative Inflammation
as Triggering Origin of Metastasis Development".
This book was published last year, I think in July,
and most everything that I'm going to discuss today,
other than what has happened since April of this year will be covered in this book.
0:46
The foreword to this book was written by Robert Weinberg who was considered by
many to be the foremost authority on cancer biology in the world.
I'm not going to read through this,
but there are just two points I wanted to bring out.
First, Dr. Weinberg thinks that whatever we find in this research is
going to be accepted only reluctantly by many in the medical oncology community.
And the other thing he mentions is a very favorable comment that this research is
likely to profoundly influence
future surgical oncology and post-surgical treatment protocols.
1:23
So this project has been going on for a very long time.
I can actually tell you when it started.
I was attending a breast cancer conference in Europe in 1993 and I walk,
I don't recall what city it was,
into the building where the conference was held and outside in the lobby I
saw posters setup by a person from a Milan National Cancer Institute.
Romano Demicheli was showing a poster.
And this immediately caught my interest.
I had been studying breast cancer for about ten years to this point.
I made a career change from doing physics research to doing breast cancer research,
and I had never seen data such as Demicheli was showing.
I'll describe this data in some detail,
but just as an overview right now,
there were 1,173 early-stage breast cancer patients with long-term follow up.
These patients were treated by surgery only.
You will see that there is a sharp peak in relapse at 18 months,
then a minimum at about 50 months,
and then it started up again as a broad shallow peak at
60 or 70 months with a long tail extending to over ten years.
This general pattern has now been identified in
over 21 independent databases from US, Europe, and Asia.
There are more than 21, but I stopped counting them.